Cargando empresa
Eikon Therapeutics, Inc.
EIKN · Nasdaq · Healthcare · Biotechnology
7,92 US$+0,1 %cierre 29 sept
- 1M
- -27,2 %
- 6M
- -21,4 %
EIKN · Nasdaq · Healthcare · Biotechnology
7,92 US$+0,1 %cierre 29 sept
Del propio 8-K de la empresa.
Eikon Therapeutics, Inc. no tiene ninguna transcripción de conferencia de resultados disponible.
“The second quarter saw meaningful acceleration of Eikon’s most important clinical programs, leading to acceptance of seven abstracts, related to all four of our current clinical candidates, for presentation at the upcoming ESMO conference in October in Madrid,”
Citado literalmente de la publicación, y mostrado solo cuando el informe lo atribuye a una persona con nombre.
Las publicaciones salen tras el cierre o antes de la apertura, así que el movimiento es el de la sesión siguiente.
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates that could eventually become lifesaving medicines. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster.
La propia descripción de la empresa, tal como aparece al pie de la publicación.
La cita y la descripción de la empresa proceden del 8-K del punto 2.02 que Eikon Therapeutics, Inc. presentó el 13 de agosto de 2026; la tabla se elabora a partir de sus informes trimestrales. Leer la publicación en EDGAR Las cotizaciones están ajustadas por splits y dividendos.